Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.56 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258294 | 0.98 | NR5A1 (0.56) | NR5A1TP53TSHRPLA2G4BLTA4H | |
| SCHEMBL19043228 | 0.94 | LTA4H (0.52) | NR5A1TP53TSHRPLA2G4BLTA4H | |
| SCHEMBL7351935 | 0.93 | NR5A1 (0.59) | NR5A1TP53TSHRPLA2G4BLTA4H | |
| SCHEMBL5252590 | 0.93 | NR5A1 (0.59) | NR5A1TP53TSHRPLA2G4BLTA4H | |
| SCHEMBL7344078 | 0.91 | NR5A1 (0.56) | NR5A1TP53TSHRPLA2G4BLTA4H | |
| SCHEMBL28084765 | 0.89 | SMN1; SMN2 (0.58) | PLA2G4A | |
| SCHEMBL8815462 | 0.86 | NR5A1 (0.53) | NR5A1TP53TSHRPLA2G4B | |
| SCHEMBL1667124 | 0.86 | NR5A1 (0.53) | NR5A1TP53TSHRPLA2G4B | |
| SCHEMBL11319340 | 0.86 | NR5A1 (0.53) | NR5A1TP53TSHRPLA2G4B | |
| SCHEMBL9265046 | 0.86 | NR5A1 (0.53) | NR5A1TP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2320886-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORP (US) | 2017-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | NR5A1 2377/4885TP53 4477/4885TSHR 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.